Eyegate Pharmaceuticals Overview
- Founded
- 1998

- Status
- Public
- Employees
- 10

- Stock Symbol
- EYEG

- Investments
- 2
- Share Price
- $6.23
- (As of Friday Closing)
Eyegate Pharmaceuticals General Information
Description
Eyegate Pharmaceuticals Inc is a US-based clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The company's lead product EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through a proprietary drug delivery system, the EyeGate II Delivery System. It mainly develops EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body.
Contact Information
- 271 Waverley Oaks Road
- Suite 108
- Waltham, MA 02452
- United States
Eyegate Pharmaceuticals Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$6.23 | $6.35 | $3.20 - $8.18 | $43.9M | 7.04M | 795K | -$2.01 |
Eyegate Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 13,829 | 34,109 | 10,312 | 9,184 |
Revenue | 0 | 2,686 | 1,653 | 408 |
EBITDA | (8,116) | (6,895) | (10,806) | (14,540) |
Net Income | (8,378) | (7,097) | (10,811) | (13,218) |
Total Assets | 9,245 | 10,113 | 14,281 | 14,305 |
Total Debt | 340 | 84 | 5 | 16 |
Eyegate Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Eyegate Pharmaceuticals‘s full profile, request access.
Request a free trialEyegate Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Eyegate Pharmaceuticals‘s full profile, request access.
Request a free trialEyegate Pharmaceuticals Comparisons
Industry
00000000
000000 0
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialEyegate Pharmaceuticals Competitors (15)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Advanced Proteome Therapeutics | Corporate Backed or Acquired | Boston, MA | 0 | 00.000 | 000000000 | 00.000 |
000000 00000000 | Formerly VC-backed | Palo Alto, CA | 00 | 00000 | 00000000 | 00000 |
0000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00.000 | 0000000000 0 | 00.000 |
0000000 | Formerly VC-backed | Jena, Germany | 00 | 00000 | 000000 - 000 | 00000 |
00000 | Venture Capital-Backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
Eyegate Pharmaceuticals Executive Team (7)
Eyegate Pharmaceuticals Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Bernard Malfroy-Camine Ph.D | Self | Board Member | 000 0000 |
Illya Maher | Eyegate Pharmaceuticals | Board Member | 000 0000 |
Morton Goldberg MD | Eyegate Pharmaceuticals | Board Member | 000 0000 |
Paul Chaney | Self | Chairman & Board Member | 000 0000 |
Praveen Tyle Ph.D | Self | Board Member | 000 0000 |
Eyegate Pharmaceuticals Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEyegate Pharmaceuticals Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 000000 | 21-Dec-2020 | 000000000000000000 | 000.00 | Drug Discovery | 0000000 0000 |
Jade Therapeutics | 07-Mar-2016 | Merger/Acquisition | 00.000 | Pharmaceuticals | 0000000 0000 |
Eyegate Pharmaceuticals Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
00000000 000000 | Drug Discovery | Vienna, Austria | 0000 |